CD8A and neoplasm: Based on our model’s high-risk score, machine learning analysis indicates that the upregulation of MDSCs and TAM M2, coupled with the downregulation of CD8+ T cells in the tumor microenvironment, may contribute to the diminished immunotherapy response observed in high-risk patients.